Insulin resistance (IR) is a novel cardiovascular risk factor that has been implicated in the pathogenesis of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Beyond its metabolic effects, insulin can potentially mediate the increased risk for CVD through its vasoactive properties. This review examines key clinical data and potential mechanisms linking IR and cardiovascular risk in CKD. While lifestyle interventions and pharmacotherapies with known insulinsensitizing properties are promising therapeutic targets to reduce the CVD burden in this population, clinical trial data on the effect of insulin sensitization on vascular function in CKD are either lacking or conflicting and are limited by small sample size and short duration of intervention. Affirming the role of IR in lowering CVD risk in CKD will require prospective randomized controlled studies with sufficient sample size and hard clinical outcomes. Future research efforts should be directed at assessing the efficacy, safety and mechanisms by which novel insulin sensitizers such as bile acid sequestrant, selective and dual peroxisome proliferator-activated receptor modulators and modulators of gut microbiota and uraemic toxins alter vascular function in patients with CKD.
I N T R O D U C T I O N
The excess risk of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD) has prompted renewed interest in exploring the contribution of novel risk factors such as insulin resistance (IR). IR may contribute to the pathogenesis of CVD in CKD through the metabolic effects of insulin as well as its vasoactive properties.
IR is present early in non-diabetic CKD patients and has been shown to correlate linearly with a decline in renal function [1] . While commencing haemodialysis (HD) has been shown to improve IR [2] , IR worsened with exposure to glucose-based peritoneal dialysate [3] . Although the underlying mechanisms for the association between IR and CKD remain unclear, numerous mechanisms such as glucose dysregulation, uraemic toxin retention, hypertension, inflammation, abnormal mineral metabolism, adiposity and acidosis have been implicated [4] (see Figure 1) .
In this review, we explore key clinical data and potential mechanisms linking IR and cardiovascular risk in CKD, with emphasis on vascular dysfunction. We will review clinical studies that assess the effect of lifestyle modification and insulinsensitizing agents on IR and vascular function in CKD. Finally, we will discuss promising new therapies and suggest areas for future research.
D E F I N I T I O N A N D M E C H A N I S M O F I R

Definition
IR is a state of impaired biological response to normal circulating levels of insulin that is accompanied by hyperinsulinaemia to maintain euglycaemia. IR is characterized by decreased insulin-mediated glucose disposal, impaired glucose utilization, inappropriate accumulation of lipids and increased lipolytic activity in fat cells. In the liver, there is increased hepatic glucose production and decreased glycogen synthesis [5] .
Mechanism
Beyond its metabolic effects, insulin is a key regulator of vasodilation, cell growth and protein metabolism through the activation of two signalling pathways [5] . In blood vessels, activation of the phosphatidylinositide 3-kinase (PI3K) pathway results in increased production of endothelial nitric oxide synthase (eNOS) and generation of the potent vasodilator nitric oxide (NO). In contrast, activation of the mitogen-activated protein kinase (MAPK) pathway triggers the production and release of adhesion molecules and endothelin 1 (ET-1), a powerful vasoconstrictor. Activation of this pathway also generates a negative feedback signal that suppresses the PI3K pathway ( Figure 2) . A fine balance must be maintained between these two opposing pathways to maintain vascular health. IR develops when there is impaired activation of the PI3K pathway and relative preservation or enhanced activation of the MAPK pathway ( Figure 3 ).
Assessment of IR
While the hyperinsulinaemic euglycaemic glucose clamp (HEGC) is considered the gold standard for directly assessing IR, simpler estimates of IR based on steady-state or dynamic testing of glucose, insulin and adipokines have largely replaced this complex investigative tool in clinical practice and epidemiological studies [6] . The rationale, advantages and limitations of these different methods have been discussed extensively elsewhere [6] . Although several indirect indices of IR, including the widely used Homeostasis Model Assessment Insulin Resistance (HOMA-IR) score, have been shown to correlate well with HEGC in CKD, better correlates have been reported with IR indices based on dynamic testing in moderate CKD [7] while adipokine-based estimates improved prediction in HD patients [8] .
There is growing evidence to suggest that IR, independent of other cardiovascular risk factors, plays a role in the pathogenesis of CVD in CKD. IR has been shown to independently predict cardiovascular mortality in some [9] but not all studies [10] of patients with CKD. In a study of non-diabetic, elderly men with CKD, IR was independently associated with all-cause and cardiovascular mortality in individuals who smoked and were physically inactive [11] . Despite evidence suggesting an association between IR and increased CVD risk in CKD, no intervention trial has been conducted to show that modulating IR per se improves cardiovascular outcomes.
I R A N D V A S C U L A R D Y S F U N C T I O N I N C K D
The underlying mechanisms for the increased risk for CVD in subjects with CKD and IR remain unclear. IR and vascular FIGURE 2: Mechanism of insulin action and implications for vascular function. Activation of the insulin receptor regulates vasomotor tone through the action of two opposing signaling pathways. Binding of insulin to its receptor initiates a conformational change that leads to the autophosphorylation of the b-subunit and rapid activation by phosphorylation of several intracellular proteins, including IRS-1. Binding of IRS-1 to the PI3-K enzyme results in increased production of eNOS and generation of the potent vasodilator NO. On the other hand, activation of the MAPK pathway triggers the release of adhesion molecules and the powerful vasoconstrictor ET-1. eNOS, endothelial nitric oxide synthase; ET-1, endothelin-1; GLUT-4, glucose transporter type 4; IRS-1, insulin receptor substrate-1; NO, nitric oxide; MAPK, mitogen-activated protein kinase; PI3-K, phosphatidylinositol-3 kinase. Potential underlying mechanisms linking insulin resistance and CKD. CKD, chronic kidney disease; FFA, free fatty acid; IR, insulin resistance; IL-6, interleukin-6; Nrf2, nuclear factor erythroid 2-related factor 2; RAAS, renin angiotensin aldosterone system; ROS, reactive oxygen species; TNF-a, tumour necrosis factor-a. 
Definition and prognostic significance of vascular dysfunction
Vascular dysfunction refers to a functional or structural disorder of the vasculature that leads to impairment in blood flow. Abnormalities in endothelial cell function lead to endothelial dysfunction (ED) while diminished arterial distensibility leads to arterial stiffness. ED precedes the development of atherosclerosis while arterial stiffness contributes to impaired diastolic coronary perfusion, subendocardial ischaemia and left ventricular hypertrophy. Measures of ED and arterial stiffness have been validated as surrogate markers for CVD risk and shown to be independent predictors of adverse cardiovascular outcomes in CKD [12, 13] .
Association between IR and vascular dysfunction
Abnormal glucose regulation plays an important role in the pathogenesis of vascular dysfunction in CKD. Clinical studies in CKD have reported an independent association between IR and impaired flow-mediated dilatation (FMD), a measure of endothelium-dependent vasodilatation [14] , and increased pulse wave velocity (PWV), a measure of arterial stiffness [15] . In contrast, glycaemic control as measured by haemoglobin A1c, but not HOMA-IR, has been independently associated with aortic PWV in non-diabetic HD patients [16] . However, the lack of association in this study may have been due to the limited sample size.
Mechanisms linking IR and vascular dysfunction
In IR states, ED can occur as a result of defective PI3K pathway signaling, which leads to decreased eNOS activity and NO bioavailability [17] . The relative activation of the MAPK pathway further contributes to ED through excess production of ET-1, proliferation of vascular smooth muscle cells (VSMCs) and release of growth factors and cytokines [17] . Arterial stiffness may occur in part as a consequence of ED through the direct action of endothelium-derived vasoactive mediators on arterial distensibility [18] . Hyperinsulinaemia may also contribute to arterial stiffness through local activation of the renin angiotensin aldosterone system (RAAS), which promotes VSMC proliferation and hypertrophy [19] .
Beyond the direct effect of hyperinsulinaemia, IR may also contribute to vascular dysfunction through its associated metabolic abnormalities. Independent of their metabolic properties, adipokines have also been shown to directly affect the endothelium through the release of vasoactive mediators [20] . Hypertension, which often coexists with IR, has been associated with reduced NO bioavailability caused by increased reactive oxygen species (ROS), activation of the RAAS and sympathetic activation [21] . The impaired endothelial function associated with postprandial hypertriglyceridaemia could be explained in part by inflammation and endothelial activation [22] . Chronic inflammation and oxidative stress, which are prevalent in CKD, may contribute directly to ED by reducing NO bioavailability [23, 24] and altering endothelial progenitor cell biology [25] .
E F F E C T O F M O D U L A T I N G I R O N V A S C U L A R F U N C T I O N I N P A T I E N T S W I T H C K D
The beneficial effect of modulating IR on vascular dysfunction using lifestyle modification and pharmacologic insulinsensitizing agents has been assessed in patients with CKD (Table 1) .
Lifestyle modification Weight loss. Obesity, which is increasingly prevalent in CKD, is a key determinant of IR. Weight loss strategies through lifestyle, surgical and pharmacologic interventions have the potential to improve IR and vascular dysfunction in CKD.
Dietary modification.
The 'right' macronutrient composition of a weight loss diet continues to be debated. Not enough is known about the effect of macronutrients on IR and vascular function, particularly in CKD. To date, there are conflicting data on whether dietary macronutrient composition has any direct effect on vascular function. In a randomized study comparing a low-carbohydrate versus low-fat diet in obese healthy 
volunteers, the low-fat diet was associated with an improvement in FMD but not fasting insulin levels, despite similar degrees of weight loss and blood pressure (BP) reduction [38] . Furthermore, while a low-carbohydrate diet lowered fasting insulin levels, FMD worsened [38] . In contrast, weight loss using calorie restriction and orlistat in healthy overweight individuals was not associated with improvement in FMD despite improvements in fasting insulin level and C-reactive protein (CRP) [39] . These studies are limited by their small sample size and short duration of intervention.
While studies to assess the effect of weight loss through dietary modification on IR and vascular function are eagerly awaited in CKD, close collaboration with a renal dietitian is recommended to minimize the risk of malnutrition and adverse metabolic effects such as hyperkalaemia and hyperphosphataemia.
Physical activity.
In CKD, several small studies provide conflicting evidence regarding the effect of physical activity on IR and/or cardiovascular risk markers. In an uncontrolled study of HD patients, supervised aerobic exercise training twice weekly for 3 months resulted in transient improvement in arterial stiffness and pulse pressure, with no effect on IR [26] . Arterial stiffness reverted to pre-training values 1 month following cessation of the exercise program. Another randomized crossover study reported improvement in arterial stiffness after 3 months of intradialytic exercise using a bicycle ergometer, but IR was not assessed [27] . In contrast, a randomized controlled trial comparing thrice-weekly intradialytic or home-based exercise training for 6 months reported no change in arterial stiffness, but IR was not evaluated [28] . Overall, there is no conclusive evidence to date for a beneficial effect of physical activity on IR or vascular dysfunction in CKD.
Bariatric surgery.
Bariatric surgery may be considered in morbidly obese individuals where dietary and lifestyle modification alone may not be sufficient to achieve significant and sustained weight loss. In a case-control study of non-diabetic, obese patients without CKD, bariatric surgery led to significant weight loss and improvement in insulin sensitivity, endothelium-dependent vasodilation and inflammation [40] . However, it is difficult to determine whether these changes were due to weight loss per se or a direct result of the procedure itself. Whether bariatric surgery can be performed safely and effectively to improve IR and vascular dysfunction in obese CKD patients remains to be determined.
Orlistat.
Orlistat promotes weight loss by reducing dietary fat absorption. In a randomized trial of obese adolescents without CKD, orlistat improved FMD, IR and dyslipidaemia when combined with dietary restriction [41] . Although orlistat has been used safely in patients with CKD [42] , widespread clinical use will be limited by its adverse gastrointestinal side effects.
Smoking cessation. Tobacco smoking is an important modifiable cardiovascular risk factor that has been strongly associated with IR and vascular dysfunction in observational studies [43] . Smoking cessation has the potential to improve IR and vascular function in CKD and should be strongly encouraged in all smokers.
Pharmacologic interventions that modulate IR
Metformin. Metformin is an insulin-sensitizing biguanide and the only oral hypoglycaemic agent that has been shown to reduce diabetes-related complications and mortality. Beyond its glucose-lowering properties, metformin has the added benefit of reducing appetite and inflammation. While metformin has been shown to improve vascular function in non-CKD subjects [44] , there is a paucity of data on its effect on vascular function in CKD due to concerns relating to increased risk of lactic acidosis.
Thiazolidinediones. Thiazolidinediones (TZDs) improve insulin sensitivity through activation of the peroxisome proliferator-activated receptor-c (PPAR-c). Although TZDs possess favourable glycaemic and pleiotropic properties that would make them ideal therapeutic agents for improving CVD outcomes in CKD, there are conflicting data regarding their cardiovascular safety [45, 46] . In an uncontrolled study of renal transplant recipients, rosiglitazone (RSG) was associated with improvement in IR and ED [29] . However, in a randomized placebo-controlled trial of patients with mild-to-moderate CKD, RSG improved insulin sensitivity, high-sensitivity (hs) CRP and von Willebrand factor but had no effect on hsinterleukin-6, vascular function and BP while increasing serum triglyceride (Tg) concentration [30] . The lack of effect on vascular function could have been due to the adverse effect of RSG on lipids [47] and possibly inflammation [48] . Other TZDs, such as pioglitazone, which have a more favourable effect on lipid profile and inflammation, could still have beneficial cardiovascular effects and warrant further investigation.
Acarbose. The a-glucosidase inhibitor, acarbose, impairs the digestion of polysaccharides, resulting in delayed absorption of glucose and reduction in postprandial hyperglycaemia. While acarbose improved postprandial endothelial function in newly diagnosed diabetic subjects, this was related to improvement in postprandial hyperglycaemia but not hyperinsulinaemia [49] . The effect of this agent on IR and vascular dysfunction has not been tested in CKD and will be limited by gastrointestinal side effects and contraindication for use in patients with advanced CKD (creatinine clearance <25 mL/min).
Incretin-based therapy. Incretin-based hypoglycaemic agents such as glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors minimizes postprandial glucose surge by delaying gastric emptying and inhibiting glucagon release. Given that these agents also possess insulin-sensitizing, anti-hypertensive, postprandial lipid-lowering, anti-inflammatory and anti-atherosclerotic properties [50] , studies to assess the effect of these agents on IR and vascular function in CKD will be of interest.
RAAS blockers. Activation of the RAAS contributes to the development of IR through increased production of ROS, which inactivates the PI3K pathway [51] . Beyond their effect on IR, 
RAAS blockers have also been shown to improve vascular function independent of BP lowering [52] . In a crossover randomized trial of peritoneal dialysis (PD) patients, telmisartan was associated with a significant reduction in plasma insulin level and HOMA-IR [31] . Another study in HD patients reported improvement in PWV independent of BP and lipid lowering with long-term administration of low-dose losartan and trandolapril [32] . Regrettably, IR was not assessed. Whether the impact of RAAS blockers on IR and vascular function in CKD translates to a reduction in cardiovascular outcomes will require large-scale clinical endpoint trials.
Vitamin D therapy. Serum 25-hydroxyvitamin D (25OHD) deficiency, which is prevalent in CKD, has been independently associated with IR [53] and vascular dysfunction independent of arterial calcification [54] . Intravenous activated vitamin D therapy has been shown to improve IR in HD patients, independent of parathyroid hormone suppression [33] . However, a 6-month randomized trial of oral cholecalciferol supplementation in 25OHD-deficient HD patients reported no effect on PWV, although IR was not assessed [34] . Data on the beneficial effect of vitamin D supplementation on IR and vascular function in CKD remain conflicting and require further controlled studies with larger sample size.
Antioxidants. Supplementation with antioxidants may improve cardiovascular outcomes in CKD, potentially through mechanisms that include IR and vascular dysfunction. While vitamin E supplementation was shown to improve the cardiovascular outcome in a randomized trial of HD patients [55] , this was not confirmed in a post hoc analysis of patients with CKD enrolled in the MICRO-HOPE (Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation) study [56] . Whether vitamin E supplementation has an effect on IR and vascular dysfunction in patients with CKD remains to be determined.
Supplementation with x3-FAs for 2 years has been associated with a reduction in the secondary endpoint of myocardial infarction in HD patients, suggesting a possible cardioprotective benefit [57] . Despite the anti-inflammatory, anti-thrombotic, anti-arrhythmic, anti-atherosclerotic, anti-hypertensive and lipid-lowering pleiotropic properties of x3-FAs, a randomized controlled trial of x3-FAs in non-diabetic CKD patients reported no significant effect on IR and arterial compliance despite BP lowering [35] .
Modifying dialysis regime. Several trials have assessed the effect of non-glucose-based solutions on IR in patients on PD [58] . A pilot randomized trial of L-carnitinine-based PD solution reported improvement in insulin sensitivity compared with glucose-based dialysate [36] . Substitution of glucose-based PD solution with icodextrin during the long dwell in non-diabetic subjects on automated PD was associated with improvement in HOMA-IR in a randomized trial [37] . Whether the use of nonglucose-based PD solutions translates in to improvement in clinical cardiovascular outcomes remains to be tested.
N O V E L A N D F U T U R E T H E R A P I E S
Bile acid sequestrant
Bile acid sequestrants (BASs) are anion-exchange resins that lower low-density lipoprotein cholesterol, total cholesterol and non-high density lipoprotein (HDL) cholesterol by binding to bile acids in the intestine to interrupt enterohepatic circulation and enhance faecal excretion of bile acids. There is renewed interest in these agents given their additional effects on glucose homeostasis, including insulin sensitivity [59] .
Although the use of BAS in CKD is associated with low risk of systemic toxicity with no report of nephrotoxicity, gastrointestinal intolerance and interference with absorption of other drugs greatly limit their use in clinical practice. Furthermore, BAS is known to increase serum Tg concentration. However, given that these agents have been associated with improvement in the risk of cardiovascular outcomes, consideration should be given to assess whether the lipid and glycaemic benefits of these agents translate in to improvements in IR and vascular function in CKD.
Selective PPAR-c modulators
Selective PPAR-c modulator (SPPARM) is a potent and selective activator of the PPAR-c receptor, which has been shown to enhance insulin sensitivity while minimizing the untoward side effects of fluid retention, weight gain, cardiac hypertrophy, adipocyte differentiation, lipid accumulation and decreased bone mass [60] . In a randomized controlled trial of patients with type 2 diabetes, the SPPARM INT131 besylate effectively lowered fasting blood glucose without causing fluid retention or weight gain compared with RSG [61] . Whether this promising new class of PPAR-c agonist will preserve the favourable effects of PPAR-c activation on insulin sensitivity, lipid metabolism, inflammation and vascular function while minimizing the adverse effects on fluid retention, cardiac failure and bone mass in CKD will require further study.
Dual PPAR modulators
Dual PPAR-a/c agonists have the potential to improve cardiovascular risk through PPAR-a-mediated improvements in lipid profile and the PPAR-c effect on insulin sensitivity. Disappointingly, drug development of several PPAR-a/c agonists (muraglitazar, tesaglitazar and aleglitazar) has been halted in recent years due to safety concerns relating to oedema, cardiac failure, excess mortality and nephrotoxicity [62] . It will be interesting to see whether further research and development uncovers newer PPAR-a/c agonists with better safety profiles.
Dual PPAR-a/d agonists exploit the lipid-lowering effects of PPAR-a activation and beneficial effects of PPAR-d activation on insulin sensitivity, fatty acid oxidation and energy regulation. In a pooled analysis of two-phase II multicentre, randomized, double-blind, placebo-controlled studies in obese subjects with dyslipidaemia and pre-diabetes, the dual PPAR-a/d agonist GFT505 was shown to improve insulin sensitivity, markers of liver dysfunction and lipid profile with a reduction in Tg and an increase in HDL cholesterol concentrations [63] . While this agent was well tolerated with no reports of weight gain, cardiac failure or cardiac event, there was a small but reversible increase in serum creatinine. Further clinical trials with adequate sample size and duration will be required to ensure the efficacy and safety of these agents.
Modulators of gut microbiota and uraemic toxins
Alterations in the gut microbiota and gut barrier function resulting in accumulation of gut-derived uraemic toxins has been implicated in the pathogenesis of IR and vascular dysfunction in CKD [64, 65] . Gut microbiota plays an important role in the regulation of host energy and fatty acid metabolism, nutrient availability, inflammation and gut barrier function [4] . Interventions targeting gut microbiota using pre-and probiotics, together with the use of adsorbents to bind gut-derived uraemic toxins, have the potential to improve IR and vascular function in CKD [64] . A randomized crossover study is currently under way to assess the effect of the co-administration of pre-and probiotics on uraemic toxins in CKD, although IR and vascular function will not be assessed [66] .
C O N C L U S I O N
IR is a well-recognized cardiovascular risk factor that is prevalent in CKD and may be an important mediator for the increased risk for CVD in this population. IR, through direct and indirect mechanisms, plays an important role in the development of vascular dysfunction, which is a known early risk marker for CVD. Non-pharmacologic and pharmacologic strategies that modulate IR have the potential to reduce the clinical cardiovascular outcome through their favourable effects on vascular dysfunction. To date, clinical data on the beneficial effect of modulating IR on vascular dysfunction and CVD risk in CKD are either lacking or conflicting. Larger controlled studies focussing on the role of lifestyle modification and pharmacologic interventions on IR and CVD risk are required to affirm the role of IR in mediating the excess cardiovascular risk in this population. 
C O N F L I C T O F I N T E R E S T S T A T E M E
